An Open Label Study of the Effects of SHR1459 in NMOSDs Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

August 15, 2022

Study Completion Date

August 15, 2022

Conditions

Neuromyelitis Optica Spectrum Disorders

Interventions

DRUG

Drug - SHR1459

Oral Tablets taken once daily for 52 weeks

Trial Locations (8)

Xiangya Hospital Of Central South University, Changsha

West China Hospital Sichuan University, Chengdu

Lanzhou University Second Hospital, Lanzhou

People's Hospital of Rizhao, Rizhao

Huashan Hospital Affiliated To Fudan University, Shanghai

First Hospital Of Shanxi Medical University, Taiyuan

Tangdu Hosiptal, Xi'an

The First Affiliated Hospital Of Zhengzhou University, Zhengzhou

All Listed Sponsors

lead

Reistone Biopharma Company Limited

INDUSTRY

NCT04670770 - An Open Label Study of the Effects of SHR1459 in NMOSDs Patients | Biotech Hunter | Biotech Hunter